| Cash flow (USD) | Q2 2026 ended May 31, 2026 | Q1 2026 ended Feb 28, 2026 | Q4 2025 ended Nov 30, 2025 | Q3 2025 ended Aug 31, 2025 | Q2 2025 ended May 31, 2025 | Q1 2025 ended Feb 28, 2025 | Q4 2024 ended Nov 30, 2024 | Q3 2024 ended Aug 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Net income | -89.53M | -87.17M | -78.22M | -86.42M | -43.46M | -56.35M | -58.55M | -48.96M |
| Depreciation and amortization | 2.25M | 2.20M | 2.12M | 2.03M | 2.24M | 2.35M | 2.55M | 2.39M |
| Stock-based compensation | 11.39M | 9.40M | 9.09M | 9.77M | 10.38M | 8.72M | 8.51M | 8.75M |
| Cash from operations | -96.57M | -71.91M | -67.83M | -57.38M | -63.16M | -61.09M | -48.75M | -42.18M |
| Capital expenditure | -1.94M | -1.04M | -5.13M | -2.71M | -2.67M | -3.48M | -2.10M | -2.35M |
| Free cash flow | -98.51M | -72.96M | -72.96M | -60.10M | -65.84M | -64.57M | -50.86M | -44.52M |
| Cash from investing | 93.00M | -123.83M | 346.0K | 50.48M | 71.50M | 25.53M | -140.82M | -21.34M |
| Cash from financing | 66.0K | 19.98M | 236.01M | 1.16M | 6.0K | 1.47M | 200.52M | 45.77M |
| Net change in cash | -3.51M | -175.76M | 168.52M | -5.75M | 8.34M | -34.08M | 10.95M | -17.75M |
From Nurix Therapeutics, Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.